GLP1R and diabetes mellitus: In a phase 3, double-blind, randomized study, 2539 adults with a BMI ≥ 30 but no diagnosis of diabetes were given tirzepatide, a dual-action gastric inhibitory peptide (GIP), and GLP-1 RAs.